Hims & Hers Health (HIMS) Acquires Peptide Facility
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Hims & Hers Acquires US-based Peptide Facility
February 21, 2025 9:00 AM ESTThe acquisition will strengthen the long-term durability of the companys domestic supply chain, helping to ensure Americans can consistently access personalized medications
SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc., the leading health and wellness platform, today announced an acquisition that will further verticalize the companys long-term ability to deliver personalized medications. The company has acquired a US-based peptide facility based in California. The acquisition will enable the company to strengthen the long-term durability of its domestic supply chain to meet the growing demand from Americans for personalized healthcare and treatment... More
